SCHEMBL6277350

SCHEMBL6277350

CCCn1cc(C(=O)OCC)c(=O)c2cc(CN3CCOCC3)oc21

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
HSD17B10 Q99714 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HPGD P15428 2/20 0.49
TSHR P16473 2/20 0.42
POLB P06746 1/20 0.42
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 1/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 1/20 0.38
STAT3 P40763 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
RAD52 P43351 1/20 0.38
UHRF1 Q96T88 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6278248 0.92 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6285075 0.91 ALDH1A1 (0.50) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6282326 0.89 ALDH1A1 (0.56) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6287389 0.88 ALDH1A1 (0.57) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6283853 0.83 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6283840 0.82 ALDH1A1 (0.61) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6283657 0.78 ALDH1A1 (0.54) ALDH1A1HSD17B10KDM4EHPGDTSHR
SCHEMBL6283579 0.77 KCNH2 (0.62) ALDH1A1MAPTKMT2AMEN1SMN1; SMN2
SCHEMBL10086152 0.73 HPGD (0.56) ALDH1A1HSD17B10KDM4EHPGDLMNA
SCHEMBL7118717 0.73 KCNH2 (0.60) ALDH1A1HSD17B10KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 ALDH1A1 1363/4885HSD17B10 3120/4885KDM4E 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.